Distinct signatures of the immune responses in low risk versus high risk neuroblastoma

Madhu Gowda, Kamar Godder, Maciej Kmieciak, Andrea Worschech, Maria Libera Ascierto, Ena Wang, Francesco M. Marincola, Masoud H. Manjili

Research output: Contribution to journalArticle

26 Citations (Scopus)


Background: Over 90% of low risk (LR) neuroblastoma patients survive whereas less than 30% of high risk (HR) patients are long term survivors. Age (children younger than 18 months old) is associated with LR disease. Considering that adaptive immune system is well developed in older children, and that T cells were shown to be involved in tumor escape and progression of cancers, we sought to determine whether HR patients may tend to show a signature of adaptive immune responses compared to LR patients who tend to have diminished T-cell responses but an intact innate immune response.Methods: We performed microarray analysis of RNA extracted from the tumor specimens of HR and LR patients. Flow cytometry was performed to determine the cellular constituents in the blood while multiplex cytokine array was used to detect the cytokine profile in patients' sera. A HR tumor cell line, SK-N-SH, was also used for detecting the response to IL-1β, a cytokines which is involved in the innate immune responses.Results: Distinct patterns of gene expression were detected in HR and LR patients indicating an active T-cell response and a diminished adaptive immune response, respectively. A diminished adaptive immune response in LR patients was evident by higher levels of IL-10 in the sera. In addition, HR patients had lower levels of circulating myeloid derived suppressor cells (MDSC) compared with a control LR patient. LR patients showed slightly higher levels of cytokines of the innate immune responses. Treatment of the HR tumor line with IL-1β induced expression of cytokines of the innate immune responses.Conclusions: This data suggests that adaptive immune responses may play an important role in the progression of HR disease whereas innate immune responses may be active in LR patients.

Original languageEnglish
Article number170
JournalJournal of Translational Medicine
Issue number1
Publication statusPublished - 6 Oct 2011
Externally publishedYes



  • Adaptive immunity
  • Innate immunity
  • Neuroblastoma
  • Prognostic biomarkers

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Gowda, M., Godder, K., Kmieciak, M., Worschech, A., Ascierto, M. L., Wang, E., Marincola, F. M., & Manjili, M. H. (2011). Distinct signatures of the immune responses in low risk versus high risk neuroblastoma. Journal of Translational Medicine, 9(1), [170]. https://doi.org/10.1186/1479-5876-9-170